Breast cancer patients with estrogen receptor mutations may benefit from early switch to fulvestrant/palbociclib
Among patients with hormone receptor-positive breast cancer treated with an aromatase inhibitor plus palbociclib (Ibrance), those who displayed a rising ESR1 mutation detected in their blood before disease progression doubled ...
Dec 9, 2021
0
3